

Abstract Type : Poster

Abstract Submission No. : PO-1252

Cost Minimization Analysis (CMA) of Generic and Branded Amlodipin in Hypertension Treatment at Sultan Daeng Radja Bulukumba Regional Hospital in 2018

Sahnaz Vivinda Putri, Asfirani Umar

Department of Management, International University Semen Indonesia, Indonesia

Objectives: Hypertension is a big challenge in Indonesia, proven by its prevalence that reached 40% in 2018 and conditions that mostly found in primary health care. In addition, hypertension management is considered to be suboptimal despite the availability of effective drugs. Amlodipine is one of anti-hypertensive that is commonly prescribed by Sultan Daeng Radja Bulukumba Regional Hospital, Sulawesi Selatan, Indonesia. Therefore, it is important to do cost minimization analysis to compare both generic and branded Amlodipine as an implementation of cost and quality control.

Methods: This retrospective study involved early and medium stage of hypertensive patients that have at least a month period of treatment from January to December 2018 using provider's perspectives of CMA (Cost Minimization Analysis).

Results: The result showed that generic form of Amlodipine is the most common anti-hypertensive drugs prescribed in Cardiology and Internal Medicine Clinic, Sultan Daeng Radja Bulukumba Regional Hospital. It was suggested that average cost of generic form of Amlodipine was 4.87 USD while branded one was 26.61 USD or approximately 5.4 times higher. Both generic and branded Amlodipine significantly reduced blood pressure, but there was not any distinguish effect between them.

Conclusions: It was concluded that generic form of Amlodipine was a less expensive and efficient choice in reducing blood pressure